1
/
of
1
Sitazit-M (Sitagliptin Hydrochloride + Metformin)
Sitazit-M (Sitagliptin Hydrochloride + Metformin)
Regular price
₱864.00 PHP
Regular price
Sale price
₱864.00 PHP
Unit price
₱28.80 each
Taxes included.
Quantity
Couldn't load pickup availability
Sitazit-M is a prescription combination medication containing sitagliptin hydrochloride and metformin, formulated to help adults with type 2 diabetes achieve better blood sugar control when used alongside diet and exercise modifications.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the body's natural incretin system. This mechanism stimulates the pancreas to release insulin at appropriate times and reduces excess glucose production by the liver, particularly when blood sugar levels are elevated. Metformin, a proven biguanide agent, complements this action by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving the body's insulin sensitivity at the peripheral level.
This dual-action combination offers multiple therapeutic advantages for diabetes management. Together, these active ingredients deliver effective HbA1c reduction, control both fasting and post-meal blood glucose levels, and maintain a significantly low risk of hypoglycemic episodes. The formulation is weight-neutral, making it suitable for long-term therapy, and provides a simplified dosing regimen that enhances patient compliance compared to taking two separate medications.
Sitazit-M is recommended when metformin monotherapy alone proves insufficient to achieve glycemic targets or when patients require a more convenient treatment option. The medication is available in both immediate-release and extended-release formulations, allowing flexibility to suit individual patient tolerance levels and personalized dosing preferences based on kidney function and overall health status.
Administration should be taken orally with meals to minimize gastrointestinal discomfort. Extended-release tablets must be swallowed whole without chewing or crushing. Always follow your healthcare provider's specific dosage instructions, as dosing is individualized based on blood sugar monitoring results and renal function assessment.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the body's natural incretin system. This mechanism stimulates the pancreas to release insulin at appropriate times and reduces excess glucose production by the liver, particularly when blood sugar levels are elevated. Metformin, a proven biguanide agent, complements this action by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving the body's insulin sensitivity at the peripheral level.
This dual-action combination offers multiple therapeutic advantages for diabetes management. Together, these active ingredients deliver effective HbA1c reduction, control both fasting and post-meal blood glucose levels, and maintain a significantly low risk of hypoglycemic episodes. The formulation is weight-neutral, making it suitable for long-term therapy, and provides a simplified dosing regimen that enhances patient compliance compared to taking two separate medications.
Sitazit-M is recommended when metformin monotherapy alone proves insufficient to achieve glycemic targets or when patients require a more convenient treatment option. The medication is available in both immediate-release and extended-release formulations, allowing flexibility to suit individual patient tolerance levels and personalized dosing preferences based on kidney function and overall health status.
Administration should be taken orally with meals to minimize gastrointestinal discomfort. Extended-release tablets must be swallowed whole without chewing or crushing. Always follow your healthcare provider's specific dosage instructions, as dosing is individualized based on blood sugar monitoring results and renal function assessment.
Share
